Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cellular Biomedicine Group stock

Own Cellular Biomedicine Group stock in just a few minutes.

Cellular Biomedicine Group, Inc is a biotechnology business based in the US. Cellular Biomedicine Group shares (CBMG) are listed on the NASDAQ and all prices are listed in US Dollars. Cellular Biomedicine Group employs 217 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cellular Biomedicine Group

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CBMG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cellular Biomedicine Group share price

Use our graph to track the performance of CBMG stocks over time.

Cellular Biomedicine Group shares at a glance

Information last updated 2021-04-18.
52-week range$11.90 - $19.76
50-day moving average $18.91
200-day moving average $18.44
Wall St. target price$19.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.32

Buy Cellular Biomedicine Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cellular Biomedicine Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellular Biomedicine Group financials

Revenue TTM $322,950
Gross profit TTM $277,542
Return on assets TTM -34.66%
Return on equity TTM -129.91%
Profit margin 0%
Book value $0.89
Market capitalisation $384.7 million

TTM: trailing 12 months

Shorting Cellular Biomedicine Group shares

There are currently 290,041 Cellular Biomedicine Group shares held short by investors – that's known as Cellular Biomedicine Group's "short interest". This figure is 2.1% up from 284,052 last month.

There are a few different ways that this level of interest in shorting Cellular Biomedicine Group shares can be evaluated.

Cellular Biomedicine Group's "short interest ratio" (SIR)

Cellular Biomedicine Group's "short interest ratio" (SIR) is the quantity of Cellular Biomedicine Group shares currently shorted divided by the average quantity of Cellular Biomedicine Group shares traded daily (recently around 83345.114942529). Cellular Biomedicine Group's SIR currently stands at 3.48. In other words for every 100,000 Cellular Biomedicine Group shares traded daily on the market, roughly 3480 shares are currently held short.

However Cellular Biomedicine Group's short interest can also be evaluated against the total number of Cellular Biomedicine Group shares, or, against the total number of tradable Cellular Biomedicine Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellular Biomedicine Group's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cellular Biomedicine Group shares in existence, roughly 10 shares are currently held short) or 0.0322% of the tradable shares (for every 100,000 tradable Cellular Biomedicine Group shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellular Biomedicine Group.

Find out more about how you can short Cellular Biomedicine Group stock.

Cellular Biomedicine Group share dividends

We're not expecting Cellular Biomedicine Group to pay a dividend over the next 12 months.

Have Cellular Biomedicine Group's shares ever split?

Cellular Biomedicine Group's shares were split on a 1:100 basis on 30 January 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellular Biomedicine Group shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Cellular Biomedicine Group shares which in turn could have impacted Cellular Biomedicine Group's share price.

Cellular Biomedicine Group share price volatility

Over the last 12 months, Cellular Biomedicine Group's shares have ranged in value from as little as $11.9 up to $19.755. A popular way to gauge a stock's volatility is its "beta".

CBMG.US volatility(beta: 1.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellular Biomedicine Group's is 1.2092. This would suggest that Cellular Biomedicine Group's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cellular Biomedicine Group overview

Cellular Biomedicine Group, Inc. , a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site